Skip to main content
Top
Published in: Heart Failure Reviews 2/2024

25-11-2023 | Cardiomyopathy

Clinical staging of Anderson-Fabry cardiomyopathy: An operative proposal

Authors: Annamaria Del Franco, Giulia Iannaccone, Maria Chiara Meucci, Rosa Lillo, Francesco Cappelli, Chiara Zocchi, Maurizio Pieroni, Francesca Graziani, Iacopo Olivotto

Published in: Heart Failure Reviews | Issue 2/2024

Login to get access

Abstract

As a slowly progressive form of hypertrophic cardiomyopathy (HCM), Anderson-Fabry disease (FD) resembles the phenotype of the most common sarcomeric forms, although significant differences in presentation and long-term progression may help determine the correct diagnosis. A variety of electrocardiographic and imaging features of FD cardiomyopathy have been described at different times in the course of the disease, and considerable discrepancies remain regarding the assessment of disease severity by individual physicians. Therefore, we here propose a practical staging of FD cardiomyopathy, in hopes it may represent the standard for cardiac evaluation and facilitate communication between specialized FD centres and primary care physicians. We identified 4 main stages of FD cardiomyopathy of increasing severity, based on available evidence from clinical and imaging studies: non-hypertrophic, hypertrophic — pre-fibrotic, hypertrophic — fibrotic, and overt dysfunction. Each stage is described and discussed in detail, following the principle that speaking a common language is critical when managing such complex patients in a multi-disciplinary and sometimes multi-centre setting.
Literature
1.
7.
go back to reference Germain DP, Elliott PM, Falissard B, Fomin VV, Hilz MJ, Jovanovic A, Kantola I, Linhart A, Mignani R, Namdar M, Nowak A, Oliveira JP, Pieroni M, Viana-Baptista M, Wanner C, Spada M (2019) The effect of enzyme replacement therapy on clinical outcomes in male patients with Fabry disease: a systematic literature review by a European panel of experts. Mol Genet Metab Rep 19:100454. https://doi.org/10.1016/j.ymgmr.2019.100454CrossRefPubMedPubMedCentral Germain DP, Elliott PM, Falissard B, Fomin VV, Hilz MJ, Jovanovic A, Kantola I, Linhart A, Mignani R, Namdar M, Nowak A, Oliveira JP, Pieroni M, Viana-Baptista M, Wanner C, Spada M (2019) The effect of enzyme replacement therapy on clinical outcomes in male patients with Fabry disease: a systematic literature review by a European panel of experts. Mol Genet Metab Rep 19:100454. https://​doi.​org/​10.​1016/​j.​ymgmr.​2019.​100454CrossRefPubMedPubMedCentral
8.
go back to reference Meucci MC, Lillo R, Del Franco A, Monda E, Iannaccone G, Baldassarre R, Di Nicola F, Parisi V, Lombardo A, Spinelli L, Biagini E, Pieroni M, Pisani A, Crea F, Iaccarino G, Limongelli G, Olivotto I, Graziani F (2023) Prognostic implications of the extent of cardiac damage in patients with Fabry disease. J Am Coll Cardiol 82:1524–1534. https://doi.org/10.1016/j.jacc.2023.07.02CrossRefPubMed Meucci MC, Lillo R, Del Franco A, Monda E, Iannaccone G, Baldassarre R, Di Nicola F, Parisi V, Lombardo A, Spinelli L, Biagini E, Pieroni M, Pisani A, Crea F, Iaccarino G, Limongelli G, Olivotto I, Graziani F (2023) Prognostic implications of the extent of cardiac damage in patients with Fabry disease. J Am Coll Cardiol 82:1524–1534. https://​doi.​org/​10.​1016/​j.​jacc.​2023.​07.​02CrossRefPubMed
11.
go back to reference Hernández-Hernández A, Diez-López C, Azevedo O, Palomino-Doza J, Alfonso F, Fuentes-Cañamero ME, Mogollón Jiménez MV, Casanova Rodríguez C, Ruz A, Tirón C, Climent V, Garcia-Pavia P (2021) Screening of Fabry disease in patients with chest pain without obstructive coronary artery disease. J Cardiovasc Transl Res 14:948–950. https://doi.org/10.1007/s12265-020-10097-2CrossRefPubMed Hernández-Hernández A, Diez-López C, Azevedo O, Palomino-Doza J, Alfonso F, Fuentes-Cañamero ME, Mogollón Jiménez MV, Casanova Rodríguez C, Ruz A, Tirón C, Climent V, Garcia-Pavia P (2021) Screening of Fabry disease in patients with chest pain without obstructive coronary artery disease. J Cardiovasc Transl Res 14:948–950. https://​doi.​org/​10.​1007/​s12265-020-10097-2CrossRefPubMed
20.
27.
39.
41.
go back to reference Hughes DA, Aguiar P, Deegan PB, Ezgu F, Frustaci A, Lidove O, Linhart A, Lubanda JC, Moon JC, Nicholls K, Niu DM, Nowak A, Ramaswami U, Reisin R, Rozenfeld P, Schiffmann R, Svarstad E, Thomas M, Torra R, Vujkovac B, Warnock DG, West ML, Johnson J, Rolfe MJ, Feriozzi S (2020) Early indicators of disease progression in Fabry disease that may indicate the need for disease-specific treatment initiation: findings from the opinion-based PREDICT-FD modified Delphi consensus initiative. BMJ Open 10:e035182. https://doi.org/10.1136/bmjopen-2019-035182CrossRefPubMedPubMedCentral Hughes DA, Aguiar P, Deegan PB, Ezgu F, Frustaci A, Lidove O, Linhart A, Lubanda JC, Moon JC, Nicholls K, Niu DM, Nowak A, Ramaswami U, Reisin R, Rozenfeld P, Schiffmann R, Svarstad E, Thomas M, Torra R, Vujkovac B, Warnock DG, West ML, Johnson J, Rolfe MJ, Feriozzi S (2020) Early indicators of disease progression in Fabry disease that may indicate the need for disease-specific treatment initiation: findings from the opinion-based PREDICT-FD modified Delphi consensus initiative. BMJ Open 10:e035182. https://​doi.​org/​10.​1136/​bmjopen-2019-035182CrossRefPubMedPubMedCentral
43.
go back to reference Vitale G, Ditaranto R, Graziani F, Tanini I, Camporeale A, Lillo R, Rubino M, Panaioli E, Di Nicola F, Ferrara V, Zanoni R, Caponetti AG, Pasquale F, Graziosi M, Berardini A, Ziacchi M, Biffi M, Santostefano M, Liguori R, Taglieri N, Nardi E, Linhart A, Olivotto I, Rapezzi C, Biagini E (2022) Standard ECG for differential diagnosis between Anderson-Fabry disease and hypertrophic cardiomyopathy. Heart 108:54–60. https://doi.org/10.1136/heartjnl-2020-318271CrossRefPubMed Vitale G, Ditaranto R, Graziani F, Tanini I, Camporeale A, Lillo R, Rubino M, Panaioli E, Di Nicola F, Ferrara V, Zanoni R, Caponetti AG, Pasquale F, Graziosi M, Berardini A, Ziacchi M, Biffi M, Santostefano M, Liguori R, Taglieri N, Nardi E, Linhart A, Olivotto I, Rapezzi C, Biagini E (2022) Standard ECG for differential diagnosis between Anderson-Fabry disease and hypertrophic cardiomyopathy. Heart 108:54–60. https://​doi.​org/​10.​1136/​heartjnl-2020-318271CrossRefPubMed
48.
go back to reference Saccheri MC, Cianciulli TF, Lax JA, Gagliardi JA, Cáceres GL, Quarin AE, Kisinovsky I, Rozenfeld PA, Reisin RC, AADELFA (2013) Two-dimensional speckle tracking echocardiography for early detection of myocardial damage in young patients with Fabry disease. Echocardiography 30:1069–1077. https://doi.org/10.1111/echo.12216 Saccheri MC, Cianciulli TF, Lax JA, Gagliardi JA, Cáceres GL, Quarin AE, Kisinovsky I, Rozenfeld PA, Reisin RC, AADELFA (2013) Two-dimensional speckle tracking echocardiography for early detection of myocardial damage in young patients with Fabry disease. Echocardiography 30:1069–1077. https://​doi.​org/​10.​1111/​echo.​12216
56.
go back to reference Augusto JB, Johner N, Shah D, Nordin S, Knott KD, Rosmini S, Lau C, Alfarih M, Hughes R, Seraphim A, Vijapurapu R, Bhuva A, Lin L, Ojrzyńska N, Geberhiwot T, Captur G, Ramaswami U, Steeds RP, Kozor R, Hughes D, Moon JC, Namdar M (2021) The myocardial phenotype of Fabry disease pre-hypertrophy and pre-detectable storage. Eur Heart J Cardiovasc Imaging 22:790–799. https://doi.org/10.1093/ehjci/jeaa101CrossRefPubMed Augusto JB, Johner N, Shah D, Nordin S, Knott KD, Rosmini S, Lau C, Alfarih M, Hughes R, Seraphim A, Vijapurapu R, Bhuva A, Lin L, Ojrzyńska N, Geberhiwot T, Captur G, Ramaswami U, Steeds RP, Kozor R, Hughes D, Moon JC, Namdar M (2021) The myocardial phenotype of Fabry disease pre-hypertrophy and pre-detectable storage. Eur Heart J Cardiovasc Imaging 22:790–799. https://​doi.​org/​10.​1093/​ehjci/​jeaa101CrossRefPubMed
57.
go back to reference Wanner C, Arad M, Baron R, Burlina A, Elliott PM, Feldt-Rasmussen U, Fomin VV, Germain DP, Hughes DA, Jovanovic A, Kantola I, Linhart A, Mignani R, Monserrat L, Namdar M, Nowak A, Oliveira JP, Ortiz A, Pieroni M, Spada M, Tylki-Szymańska A, Tøndel C, Viana-Baptista M, Weidemann F, Hilz MJ (2018) European expert consensus statement on therapeutic goals in Fabry disease. Mol Genet Metab 124:189–203. https://doi.org/10.1016/j.ymgme.2018.06.004CrossRefPubMed Wanner C, Arad M, Baron R, Burlina A, Elliott PM, Feldt-Rasmussen U, Fomin VV, Germain DP, Hughes DA, Jovanovic A, Kantola I, Linhart A, Mignani R, Monserrat L, Namdar M, Nowak A, Oliveira JP, Ortiz A, Pieroni M, Spada M, Tylki-Szymańska A, Tøndel C, Viana-Baptista M, Weidemann F, Hilz MJ (2018) European expert consensus statement on therapeutic goals in Fabry disease. Mol Genet Metab 124:189–203. https://​doi.​org/​10.​1016/​j.​ymgme.​2018.​06.​004CrossRefPubMed
68.
go back to reference Bernardini A, Camporeale A, Pieroni M, Pieruzzi F, Figliozzi S, Lusardi P, Spada M, Mignani R, Burlina A, Carubbi F, Battaglia Y, Graziani F, Pica S, Tondi L, Chow K, Boveri S, Olivotto I, Lombardi M (2020) Atrial dysfunction assessed by cardiac magnetic resonance as an early marker of Fabry cardiomyopathy. JACC Cardiovasc Imaging 13:2262–2264. https://doi.org/10.1016/j.jcmg.2020.05.011CrossRefPubMed Bernardini A, Camporeale A, Pieroni M, Pieruzzi F, Figliozzi S, Lusardi P, Spada M, Mignani R, Burlina A, Carubbi F, Battaglia Y, Graziani F, Pica S, Tondi L, Chow K, Boveri S, Olivotto I, Lombardi M (2020) Atrial dysfunction assessed by cardiac magnetic resonance as an early marker of Fabry cardiomyopathy. JACC Cardiovasc Imaging 13:2262–2264. https://​doi.​org/​10.​1016/​j.​jcmg.​2020.​05.​011CrossRefPubMed
70.
go back to reference Roller FC, Fuest S, Meyer M, Harth S, Gündüz D, Bauer P, Schneider C, Rolfs A, Krombach GA, Tanislav C (2019) Assessment of cardiac involvement in Fabry disease (FD) with native T1 mapping. Rofo 191:932–939. English. https://doi.org/10.1055/a-0836-2723 Roller FC, Fuest S, Meyer M, Harth S, Gündüz D, Bauer P, Schneider C, Rolfs A, Krombach GA, Tanislav C (2019) Assessment of cardiac involvement in Fabry disease (FD) with native T1 mapping. Rofo 191:932–939. English. https://​doi.​org/​10.​1055/​a-0836-2723
80.
go back to reference Lenders M, Nordbeck P, Kurschat C, Eveslage M, Karabul N, Kaufeld J, Hennermann JB, Patten M, Cybulla M, Müntze J, Üçeyler N, Liu D, Das AM, Sommer C, Pogoda C, Reiermann S, Duning T, Gaedeke J, von Cossel K, Blaschke D, Brand SM, Mann WA, Kampmann C, Muschol N, Canaan-Kühl S, Brand E (2022) Treatment of Fabry disease management with migalastat-outcome from a prospective 24 months observational multicenter study (FAMOUS). Eur Heart J Cardiovasc Pharmacother 8:272–281. https://doi.org/10.1093/ehjcvp/pvab025CrossRefPubMed Lenders M, Nordbeck P, Kurschat C, Eveslage M, Karabul N, Kaufeld J, Hennermann JB, Patten M, Cybulla M, Müntze J, Üçeyler N, Liu D, Das AM, Sommer C, Pogoda C, Reiermann S, Duning T, Gaedeke J, von Cossel K, Blaschke D, Brand SM, Mann WA, Kampmann C, Muschol N, Canaan-Kühl S, Brand E (2022) Treatment of Fabry disease management with migalastat-outcome from a prospective 24 months observational multicenter study (FAMOUS). Eur Heart J Cardiovasc Pharmacother 8:272–281. https://​doi.​org/​10.​1093/​ehjcvp/​pvab025CrossRefPubMed
84.
go back to reference Linhart A, Germain DP, Olivotto I, Akhtar MM, Anastasakis A, Hughes D, Namdar M, Pieroni M, Hagège A, Cecchi F, Gimeno JR, Limongelli G, Elliott P (2020) An expert consensus document on the management of cardiovascular manifestations of Fabry disease. Eur J Heart Fail 22:1076–1096. https://doi.org/10.1002/ejhf.1960CrossRefPubMed Linhart A, Germain DP, Olivotto I, Akhtar MM, Anastasakis A, Hughes D, Namdar M, Pieroni M, Hagège A, Cecchi F, Gimeno JR, Limongelli G, Elliott P (2020) An expert consensus document on the management of cardiovascular manifestations of Fabry disease. Eur J Heart Fail 22:1076–1096. https://​doi.​org/​10.​1002/​ejhf.​1960CrossRefPubMed
85.
go back to reference Authors TF, members; Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, Charron P, Hagege AA, Lafont A, Limongelli G, Mahrholdt H, McKenna WJ, Mogensen J, Nihoyannopoulos P, Nistri S, Pieper PG, Pieske B, Rapezzi C, Rutten FH, Tillmanns C, Watkins H (2014) 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J 35:2733–2779. https://doi.org/10.1093/eurheartj/ehu284 Authors TF, members; Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, Charron P, Hagege AA, Lafont A, Limongelli G, Mahrholdt H, McKenna WJ, Mogensen J, Nihoyannopoulos P, Nistri S, Pieper PG, Pieske B, Rapezzi C, Rutten FH, Tillmanns C, Watkins H (2014) 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J 35:2733–2779. https://​doi.​org/​10.​1093/​eurheartj/​ehu284
86.
go back to reference Magage S, Linhart A, Bultas J, Vojacek J, Mates M, Palecek T, Popelova J, Tintera J, Aschermann M, Goldman ME, Desnick RJ (2005) Fabry disease: percutaneous transluminal septal myocardial ablation markedly improved symptomatic left ventricular hypertrophy and outflow tract obstruction in a classically affected male. Echocardiography 22:333–339. https://doi.org/10.1111/j.1540-8175.2005.03191.xCrossRefPubMed Magage S, Linhart A, Bultas J, Vojacek J, Mates M, Palecek T, Popelova J, Tintera J, Aschermann M, Goldman ME, Desnick RJ (2005) Fabry disease: percutaneous transluminal septal myocardial ablation markedly improved symptomatic left ventricular hypertrophy and outflow tract obstruction in a classically affected male. Echocardiography 22:333–339. https://​doi.​org/​10.​1111/​j.​1540-8175.​2005.​03191.​xCrossRefPubMed
94.
go back to reference Meucci MC, Lillo R, Lombardo A, Lanza GA, Bootsma M, Butcher SC, Massetti M, Manna R, Bax JJ, Crea F, Ajmone Marsan N, Graziani F (2023) Comparative analysis of right ventricular strain in Fabry cardiomyopathy and sarcomeric hypertrophic cardiomyopathy. Eur Heart J Cardiovasc Imaging 24:542–551. https://doi.org/10.1093/ehjci/jeac151 Meucci MC, Lillo R, Lombardo A, Lanza GA, Bootsma M, Butcher SC, Massetti M, Manna R, Bax JJ, Crea F, Ajmone Marsan N, Graziani F (2023) Comparative analysis of right ventricular strain in Fabry cardiomyopathy and sarcomeric hypertrophic cardiomyopathy. Eur Heart J Cardiovasc Imaging 24:542–551. https://​doi.​org/​10.​1093/​ehjci/​jeac151
97.
go back to reference Ortiz A, Abiose A, Bichet DG, Cabrera G, Charrow J, Germain DP, Hopkin RJ, Jovanovic A, Linhart A, Maruti SS, Mauer M, Oliveira JP, Patel MR, Politei J, Waldek S, Wanner C, Yoo HW, Warnock DG (2016) Time to treatment benefit for adult patients with Fabry disease receiving agalsidase β: data from the Fabry Registry. J Med Genet 53:495–502. https://doi.org/10.1136/jmedgenet-2015-103486CrossRefPubMed Ortiz A, Abiose A, Bichet DG, Cabrera G, Charrow J, Germain DP, Hopkin RJ, Jovanovic A, Linhart A, Maruti SS, Mauer M, Oliveira JP, Patel MR, Politei J, Waldek S, Wanner C, Yoo HW, Warnock DG (2016) Time to treatment benefit for adult patients with Fabry disease receiving agalsidase β: data from the Fabry Registry. J Med Genet 53:495–502. https://​doi.​org/​10.​1136/​jmedgenet-2015-103486CrossRefPubMed
98.
go back to reference Takenaka T, Teraguchi H, Yoshida A, Taguchi S, Ninomiya K, Umekita Y, Yoshida H, Horinouchi M, Tabata K, Yonezawa S, Yoshimitsu M, Higuchi K, Nakao S, Anan R, Minagoe S, Tei C (2008) Terminal stage cardiac findings in patients with cardiac Fabry disease: an electrocardiographic, echocardiographic, and autopsy study. J Cardiol 51:50–59. https://doi.org/10.1016/j.jjcc.2007.12.001CrossRefPubMed Takenaka T, Teraguchi H, Yoshida A, Taguchi S, Ninomiya K, Umekita Y, Yoshida H, Horinouchi M, Tabata K, Yonezawa S, Yoshimitsu M, Higuchi K, Nakao S, Anan R, Minagoe S, Tei C (2008) Terminal stage cardiac findings in patients with cardiac Fabry disease: an electrocardiographic, echocardiographic, and autopsy study. J Cardiol 51:50–59. https://​doi.​org/​10.​1016/​j.​jjcc.​2007.​12.​001CrossRefPubMed
99.
go back to reference Graziani F, Leccisotti L, Lillo R, Bruno I, Ingrasciotta G, Leone AM, Montone RA, Marano R, Rovere G, Indovina L, Camporeale A, Pieroni M, Giordano A, Manna R, Lombardo A, Massetti M, Lanza GA, Crea F (2022) Coronary microvascular dysfunction is associated with a worse cardiac phenotype in patients with Fabry disease. JACC Cardiovasc Imaging 15:1518–1520. https://doi.org/10.1016/j.jcmg.2022.03.004CrossRefPubMed Graziani F, Leccisotti L, Lillo R, Bruno I, Ingrasciotta G, Leone AM, Montone RA, Marano R, Rovere G, Indovina L, Camporeale A, Pieroni M, Giordano A, Manna R, Lombardo A, Massetti M, Lanza GA, Crea F (2022) Coronary microvascular dysfunction is associated with a worse cardiac phenotype in patients with Fabry disease. JACC Cardiovasc Imaging 15:1518–1520. https://​doi.​org/​10.​1016/​j.​jcmg.​2022.​03.​004CrossRefPubMed
100.
go back to reference Graziani F, Lillo R, Biagini E, Limongelli G, Autore C, Pieroni M, Lanzillo C, Calò L, Musumeci MB, Ingrasciotta G, Minnucci M, Ditaranto R, Milazzo A, Zocchi C, Rubino M, Lanza GA, Olivotto I, Crea F (2022) Myocardial infarction with non-obstructive coronary arteries in hypertrophic cardiomyopathy vs Fabry disease. Int J Cardiol 369:29–32. https://doi.org/10.1016/j.ijcard.2022.07.046CrossRefPubMed Graziani F, Lillo R, Biagini E, Limongelli G, Autore C, Pieroni M, Lanzillo C, Calò L, Musumeci MB, Ingrasciotta G, Minnucci M, Ditaranto R, Milazzo A, Zocchi C, Rubino M, Lanza GA, Olivotto I, Crea F (2022) Myocardial infarction with non-obstructive coronary arteries in hypertrophic cardiomyopathy vs Fabry disease. Int J Cardiol 369:29–32. https://​doi.​org/​10.​1016/​j.​ijcard.​2022.​07.​046CrossRefPubMed
103.
go back to reference Biegstraaten M, Arngrímsson R, Barbey F, Boks L, Cecchi F, Deegan PB, Feldt-Rasmussen U, Geberhiwot T, Germain DP, Hendriksz C, Hughes DA, Kantola I, Karabul N, Lavery C, Linthorst GE, Mehta A, van de Mheen E, Oliveira JP, Parini R, Ramaswami U, Rudnicki M, Serra A, Sommer C, Sunder-Plassmann G, Svarstad E, Sweeb A, Terryn W, Tylki-Szymanska A, Tøndel C, Vujkovac B, Weidemann F, Wijburg FA, Woolfson P, Hollak CE (2015) Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document. Orphanet J Rare Dis 10:36. https://doi.org/10.1186/s13023-015-0253-6CrossRefPubMedPubMedCentral Biegstraaten M, Arngrímsson R, Barbey F, Boks L, Cecchi F, Deegan PB, Feldt-Rasmussen U, Geberhiwot T, Germain DP, Hendriksz C, Hughes DA, Kantola I, Karabul N, Lavery C, Linthorst GE, Mehta A, van de Mheen E, Oliveira JP, Parini R, Ramaswami U, Rudnicki M, Serra A, Sommer C, Sunder-Plassmann G, Svarstad E, Sweeb A, Terryn W, Tylki-Szymanska A, Tøndel C, Vujkovac B, Weidemann F, Wijburg FA, Woolfson P, Hollak CE (2015) Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document. Orphanet J Rare Dis 10:36. https://​doi.​org/​10.​1186/​s13023-015-0253-6CrossRefPubMedPubMedCentral
Metadata
Title
Clinical staging of Anderson-Fabry cardiomyopathy: An operative proposal
Authors
Annamaria Del Franco
Giulia Iannaccone
Maria Chiara Meucci
Rosa Lillo
Francesco Cappelli
Chiara Zocchi
Maurizio Pieroni
Francesca Graziani
Iacopo Olivotto
Publication date
25-11-2023
Publisher
Springer US
Published in
Heart Failure Reviews / Issue 2/2024
Print ISSN: 1382-4147
Electronic ISSN: 1573-7322
DOI
https://doi.org/10.1007/s10741-023-10370-x

Other articles of this Issue 2/2024

Heart Failure Reviews 2/2024 Go to the issue